Testosterone Litigation: Low-T may mean low lifespan for testosterone patients
The Public Library of Science (PLOS) has concluded that testosterone replacement therapy may greatly increase the risk of stroke, heart attack and pulmonary embolism in some men. Within 90 days of starting testosterone therapy, men aged 65 and older had double the risk of heart attack. For men younger than 65, who already had a history of heart problems, that risk tripled. In addition, once a patient has started testosterone therapy, they may not be able to stop. According to Dr. Gregory Broderick in a recent interview with CNN, “[o]nce you start, your body begins shutting down natural production of the hormone, thinking it is no longer needed.”
The study cited by the PLOS examined medical records from over 55,000 men. This is but one study of several that has linked testosterone replacement therapy to significant and serious cardiac side effects.
The brand leader in this market is Androgel. Androgel holds 50% of the testosterone replacement therapy market. Androgel has obtained this market share through aggressive and creative marketing strategies and by targeted sales campaigns to prescribing doctors. Even though the FDA has approved testosterone replacement therapy for limited uses, this aggressive marketing campaign has pushed doctors into prescribing testosterone to men who have no medical need for it, or who merely want to feel young again. This practice of off-label use has put thousands of men in danger of heart attack, stroke and other cardiac events.
If you or a loved one has suffered a cardiac event, such as heart attack, stroke or pulmonary embolism within 90 days of starting testosterone therapy, contact the Law Firm of Price & Randle, LLC for a free case evaluation.